Ivosidenib
Ivosidenib
Definition
An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.
Also known as AG 120, AG-120, AG120, IVOSIDENIB, Tibsovo — per NCIT
Also identified as
- ATC L01XM02 per RXNORM
- NCIT NCIT:C114383 per NCIT
- SCTID 773137008 per RXNORM
- SCTID 773232006 per RXNORM
- UNII Q2PCN8MAM6 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Acute myeloid leukemia | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.